



**2018 Alliance Fall Group Meeting**  
Loews Chicago O'Hare Hotel – Rosemont, IL  
Friday, November 12, 2018  
2:00-6:00PM  
Pollock A

## **Multiple Myeloma Committee Meeting Agenda**

Chair(s): Paul Richardson, MD

Vice-Chairs: Philip McCarthy, MD

### **I. Welcome and Introductions**

### **II. Alliance Studies (Completed and Ongoing)**

- a. A061202: Phase I/II Pom/Dex +/- Ixazomib (MLN9708) in Relapsed and Refractory MM (RR MM) – Peter Voorhees
- b. A061402: Solitary Osseous Plasmacytoma – Anuj Mahindra
- c. AFT29: Phase II RVd +/- Dara (the Griffin trial) in Newly Diagnosed (ND) MM – Peter Voorhees, Paul Richardson
- d. CALGB 100104 Phase III and derived studies – Phil McCarthy
- e. Auto/Allo in MM (CALGB 100001; Phase I/II) - Phil McCarthy
- f. IFM/DFCI 2009 Study (Phase III BMT CTN 1304; the Determination trial) – Paul Richardson

### **III. Alliance Studies (Activation Pending)**

- a. AFT15: Phase I/II Ibrutinib + Rd in RR MM – Yvonne Efebera

### **IV. Endorsed Studies**

- a. ECOG – E1A11: Phase III RVd vs KRd in ND MM – Edward Faber
- b. ECOG – E3A06: Phase III Smoldering Myeloma (lenalidomide vs placebo) – Anuj Mahindra
- c. SWOG – S1211: Phase III RVd +/- Elo vs KRd +/- Elo; for ND high risk MM – Peter Voorhees
- d. SWOG – S1304: Phase II Carfilzomib in RR MM (completed; results pending) – Peter Voorhees
- e. BMT CTN 1302: Phase II RIC Allo-SCT followed by Ixazomib maintenance in ND MM – Cristina Gasparetto
- f. Amyloid Study – Heather Landau & Hani Hassoun

### **V. Treatment Concepts and New Initiatives: Updates and New Proposals**

- a. AFT35: Phase I/II PVd Dara in RR MM – Hani Hassoun, Paul Richardson
- b. AFT41: Phase II RID +/- Dara in non-SCT eligible ND MM – Betsy O'Donnell, Paul Richardson, Noopur Raje

- c. Therapeutic Subcommittee for MM in Older Adults – Tanya Wildes, Sascha Tuchman, Ashley Rosko, Betsy O’Donnell

**VI. New Proposals**

- a. Maintenance after 2nd transplant with Venetoclax – Sarah Holstein and Phil McCarthy
- b. Rev +/- ACY241 S/PASCT– Sarah Holstein & Philip McCarthy
- c. Optimal duration of lenalidomide maintenance in MRD negative ND MM patients post ASCT – Peter Voorhees
- d. Plasma Cell Leukemia- Peter Voorhees
- e. CNS Myeloma- Paul G. Richardson
- f. Pomalidomide + Ixazomib and dexamethasone in relapsed refractory multiple myeloma (twice a week Ixazomib, in patients who have received 2 or more lines of therapy)- Giada Bianchi, Paul G. Richardson
- g. Phase II CyBorD-Dara in monoclonal gammopathy-associated kidney diseases – Hani Hassoun, Sasha Tuchman, Anuj Mahindra, Giada Bianchi

**VII. Correlative Science Studies**

- a. A151210/ A151211: Understanding the molecular basis for myeloid cell transformation in the plasma cell dyscrasias and second malignancies in myeloma – Phil McCarthy
- b. Hevylite assay vs standard assays for disease measurement – Hani Hassoun

**VIII. Dissemination and Implementation (D&I) Committee Presentation**

Sarah Blair MD, FACS and/or Diana Dickson-Witmer MD, FACS